138
Views
4
CrossRef citations to date
0
Altmetric
Review

Reducing lung function decline in patients with idiopathic pulmonary fibrosis: potential of nintedanib

, &
Pages 503-510 | Published online: 19 Jun 2013

References

  • Maher TM Wells AU Laurent GJ Idiopathic pulmonary fibrosis: multiple causes and multiple mechanisms? Eur Respir Journal 2007 30 5 835 839
  • Navaratnam V Fleming KM West J The rising incidence of idiopathic pulmonary fibrosis in the UK Thorax 2011 66 6 462 467 21525528
  • Gribbin J Hubbard RB Le JI Smith CJ West J Tata LJ Incidence and mortality of idiopathic pulmonary fibrosis and sarcoidosis in the UK Thorax 2006 61 11 980 985 16844727
  • Raghu G Weycker D Edelsberg J Bradford WZ Oster G Incidence and prevalence of idiopathic pulmonary fibrosis Am J Respir Crit Care Med 2006 174 7 810 816 16809633
  • Navaratnam V Fogarty A Glendening R McKeever T Hubbard RB The increasing secondary care burden of idiopathic pulmonary fibrosis: hospital admission trends in England from 1998 to 2010 Chest Epub 9 24 2012
  • Ley B Collard HR King TEJr Clinical course and prediction of survival in idiopathic pulmonary fibrosis Am J Respir Crit Care Med 2011 183 4 431 440 20935110
  • Datta A Scotton CJ Chambers RC Novel therapeutic approaches for pulmonary fibrosis Br J Pharmacol 2011 163 1 141 172 21265830
  • King TEJr Pardo A Selman M Idiopathic pulmonary fibrosis Lancet 2011 378 9807 1949 1961 21719092
  • Maher TM Pirfenidone in idiopathic pulmonary fibrosis Drugs Today (Barc) 2010 46 7 473 482 20683502
  • Roth GJ Heckel A Colbatzky F Design, synthesis, and evaluation of indolinones as triple angiokinase inhibitors and the discovery of a highly specific 6-methoxycarbonyl-substituted indolinone (BIBF 1120) J Med Chem 2009 52 14 4466 4480 19522465
  • Richeldi L Costabel U Selman M Efficacy of a tyrosine kinase inhibitor in idiopathic pulmonary fibrosis N Engl J Med 2011 365 12 1079 1087 21992121
  • Hilberg F Roth GJ Krssak M BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy Cancer Res 2008 68 12 4774 4782 18559524
  • Santos ES Gomez JE Raez LE Targeting angiogenesis from multiple pathways simultaneously: BIBF 1120, an investigational novel triple angiokinase inhibitor Invest New Drugs 2012 30 3 1261 1269 21350804
  • Ellis PM Kaiser R Zhao Y Stopfer P Gyorffy S Hanna N Phase I open-label study of continuous treatment with BIBF 1120, a triple angiokinase inhibitor, and pemetrexed in pretreated non-small cell lung cancer patients Clinical Cancer Res 2010 16 10 2881 2889 20460487
  • du Bois A Huober J Stopfer P A phase I open-label dose-escalation study of oral BIBF 1120 combined with standard paclitaxel and carboplatin in patients with advanced gynecological malignancies Ann Oncol 2010 21 2 370 375 19889612
  • Doebele RC Conkling P Traynor AM A phase I, open-label dose-escalation study of continuous treatment with BIBF 1120 in combination with paclitaxel and carboplatin as first-line treatment in patients with advanced non-small-cell lung cancer Ann Oncol 2012 23 8 2094 2102 22345119
  • Kropff M Kienast J Bisping G An open-label dose-escalation study of BIBF 1120 in patients with relapsed or refractory multiple myeloma Anticancer Res 2009 29 10 4233 4238 19846979
  • Ledermann JA Hackshaw A Kaye S Randomized phase II placebo-controlled trial of maintenance therapy using the oral triple angiokinase inhibitor BIBF 1120 after chemotherapy for relapsed ovarian cancer J Clin Oncol 2011 29 28 3798 3804 21859991
  • Chaudhary NI Roth GJ Hilberg F Inhibition of PDGF, VEGF and FGF signalling attenuates fibrosis Eur Respir J 2007 29 5 976 985 17301095
  • Taeger J Moser C Hellerbrand C Targeting FGFR/PDGFR/VEGFR impairs tumor growth, angiogenesis, and metastasis by effects on tumor cells, endothelial cells, and pericytes in pancreatic cancer Mol Cancer Ther 2011 10 11 2157 2167 21885862
  • Akhurst RJ Hata A Targeting the TGFbeta signalling pathway in disease Nat Rev Drug Discov 2012 11 10 790 811 23000686
  • Antoniades HN Bravo MA Avila RE Platelet-derived growth factor in idiopathic pulmonary fibrosis J Clin Invest 1990 86 4 1055 1064 2170444
  • Bonner JC Regulation of PDGF and its receptors in fibrotic diseases Cytokine and Growth Factor Reviews 2004 15 4 255 273 15207816
  • Battegay EJ Raines EW Colbert T Ross R TNF-alpha stimulation of fibroblast proliferation. Dependence on platelet-derived growth factor (PDGF) secretion and alteration of PDGF receptor expression Journal of immunology 1995 154 11 6040 6047
  • Battegay EJ Raines EW Seifert RA Bowen-Pope DF Ross R TGF-beta induces bimodal proliferation of connective tissue cells via complex control of an autocrine PDGF loop Cell 1990 63 3 515 524 2171777
  • Kolb M Margetts PJ Anthony DC Pitossi F Gauldie J Transient expression of IL-1beta induces acute lung injury and chronic repair leading to pulmonary fibrosis J Clin Invest 2001 107 12 1529 1536 11413160
  • Yoshida M Sakuma J Hayashi S A histologically distinctive interstitial pneumonia induced by overexpression of the interleukin 6, transforming growth factor beta 1, or platelet-derived growth factor B gene Proc Nat Academy of Sciences of the United States of America 1995 92 21 9570 9574
  • Rice AB Moomaw CR Morgan DL Bonner JC Specific inhibitors of platelet-derived growth factor or epidermal growth factor receptor tyrosine kinase reduce pulmonary fibrosis in rats Am Journal Pathol 1999 155 1 213 221 10393853
  • Abdollahi A Li M Ping G Inhibition of platelet-derived growth factor signaling attenuates pulmonary fibrosis J Exp Med 2005 201 6 925 935 15781583
  • Martinet Y Rom WN Grotendorst GR Martin GR Crystal RG Exaggerated spontaneous release of platelet-derived growth factor by alveolar macrophages from patients with idiopathic pulmonary fibrosis N Engl J Med 1987 317 4 202 209 3600711
  • Homma S Nagaoka I Abe H Localization of platelet-derived growth factor and insulin-like growth factor I in the fibrotic lung Am J Respir Crit Care Med 1995 152 6 Pt 1 2084 2089 8520779
  • Daniels CE Wilkes MC Edens M Imatinib mesylate inhibits the profibrogenic activity of TGF-beta and prevents bleomycin-mediated lung fibrosis J Clin Invest 2004 114 9 1308 1316 15520863
  • Daniels CE Lasky JA Limper AH Mieras K Gabor E Schroeder DR Imatinib treatment for idiopathic pulmonary fibrosis: randomized placebo-controlled trial results Am J Respir Crit Care Med 2010 181 6 604 610 20007927
  • Gurujeyalakshmi G Hollinger MA Giri SN Pirfenidone inhibits PDGF isoforms in bleomycin hamster model of lung fibrosis at the translational level Am Journal Physiol 1999 276 2 Pt 1 L311 L318 9950894
  • Henke C Fiegel V Peterson M Identification and partial characterization of angiogenesis bioactivity in the lower respiratory tract after acute lung injury J Clin Invest 1991 88 4 1386 1395 1717512
  • Inoue Y King TEJr Barker E Daniloff E Newman LS Basic fibroblast growth factor and its receptors in idiopathic pulmonary fibrosis and lymphangioleiomyomatosis Am J Respir Crit Care Med 2002 166 5 765 773 12204879
  • Fan H Duan Y Zhou H Selection of peptide ligands binding to fibroblast growth factor receptor 1 IUBMB Life 2002 54 2 67 72 12440521
  • Calandrella N Risuleo G Scarsella G Reduction of cell proliferation induced by PD166866: an inhibitor of the basic fibroblast growth factor J Exp Cin Cancer Res 2007 26 3 405 409
  • Yu ZH Wang DD Zhou ZY He SL Chen AA Wang J Mutant soluble ectodomain of fibroblast growth factor receptor-2 IIIc attenuates bleomycin-induced pulmonary fibrosis in mice Biol Pharm Bull 2012 35 5 731 736 22687409
  • Olsson AK Dimberg A Kreuger J Claesson-Welsh L VEGF receptor signalling – in control of vascular function Nat Rev Mol Cell Biol 2006 7 5 359 371 16633338
  • Farkas L Farkas D Ask K VEGF ameliorates pulmonary hypertension through inhibition of endothelial apoptosis in experimental lung fibrosis in rats J Clin Invest 2009 119 5 1298 1311 19381013
  • Renzoni EA Walsh DA Salmon M Interstitial vascularity in fibrosing alveolitis Am J Respir Crit Care Med 2003 167 3 438 443 12406847
  • Keane MP Arenberg DA Lynch JPIII The CXC chemokines, IL-8 and IP-10, regulate angiogenic activity in idiopathic pulmonary fibrosis J Immunol 1997 159 3 1437 1443 9233641
  • Nissen LJ Cao R Hedlund EM Angiogenic factors FGF2 and PDGF-BB synergistically promote murine tumor neovascularization and metastasis J Clin Invest 2007 117 10 2766 2777 17909625
  • Hamada N Kuwano K Yamada M Anti-vascular endothelial growth factor gene therapy attenuates lung injury and fibrosis in mice J Immunol 2005 175 2 1224 1231 16002726
  • Mross K Stefanic M Gmehling D Phase I study of the angiogenesis inhibitor BIBF 1120 in patients with advanced solid tumors Clin Cancer Res 2010 16 1 311 319 20028771
  • Okamoto I Kaneda H Satoh T Phase I safety, pharmacokinetic, and biomarker study of BIBF 1120, an oral triple tyrosine kinase inhibitor in patients with advanced solid tumors Mol Cancer Ther 2010 9 10 2825 2833 20688946
  • Stopfer P Rathgen K Bischoff D Pharmacokinetics and metabolism of BIBF 1120 after oral dosing to healthy male volunteers Xenobiotica 2011 41 4 297 311 21204634
  • Gori B Ricciardi S Fulvi A Intagliata S Del Signore E de Marinis F New antiangiogenics in non-small cell lung cancer treatment: vargatef (BIBF 1120) and beyond Ther Clin Risk Manag 2011 7 429 440 22241943
  • Raghu G Collard HR Anstrom KJ Idiopathic pulmonary fibrosis: clinically meaningful primary endpoints in phase 3 clinical trials Am J Respir Crit Care Med 2012 185 10 1044 1048 22505745
  • du Bois RM Nathan SD Richeldi L Schwarz MI Noble PW Idiopathic pulmonary fibrosis: lung function is a clinically meaningful endpoint for phase III trials Am J Respir Crit Care Med 2012 186 8 712 715 22798316
  • Wells AU Behr J Costabel U European IPFCG Hot of the breath: mortality as a primary end-point in IPF treatment trials: the best is the enemy of the good Thorax 2012 67 11 938 940 23047830
  • du Bois RM Weycker D Albera C Ascertainment of individual risk of mortality for patients with idiopathic pulmonary fibrosis Am J Respir Crit Care Med 2011 184 4 459 466 21616999
  • Taniguchi H Ebina M Kondoh Y Pirfenidone in idiopathic pulmonary fibrosis Eur Respir J 2010 35 4 821 829 19996196
  • Collard HR Idiopathic pulmonary fibrosis and pirfenidone Eur Respir J 2010 35 4 728 729 20356985
  • Richeldi L Brown KK Costabel U Efficacy of the tyrosine kinase inhibitor BIBF 1120 in patients with IPF: consistent pattern of primary endpoint results in sensitivity analyses of the TOMORROW trial Am J Respir Crit Care Med 2012 185 1 Meeting Abstracts A3633
  • Brown KK Richeldi L Costabel U Treatment of IPF with the tyrosine kinase inhibitor BIBF 1120: patient-reported outcomes in the TOMORROW trial Am Journal of Respiratory and Critical Care Medicine 2012 185 1 Meeting Abstracts A3634
  • Swigris JJ Brown KK Behr J The SF-36 and SGRQ: validity and first look at minimum important differences in IPF Respir Med 2010 104 2 296 304 19815403
  • Collard HR Moore BB Flaherty KR Acute exacerbations of idiopathic pulmonary fibrosis Am J Respir Crit Care Med 2007 176 7 636 643 17585107
  • Huie TJ Olson AL Cosgrove GP A detailed evaluation of acute respiratory decline in patients with fibrotic lung disease: aetiology and outcomes Respirology 2010 15 6 909 917 20546190
  • Azuma A Nukiwa T Tsuboi E Double-blind, placebo-controlled trial of pirfenidone in patients with idiopathic pulmonary fibrosis Am J Respir Crit Care Med 2005 171 9 1040 1047 15665326
  • Noble PW Albera C Bradford WZ Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials Lancet 2011 377 9779 1760 1769 21571362
  • Bouche O Maindrault-Goebel F Ducreux M Phase II trial of weekly alternating sequential BIBF 1120 and afatinib for advanced colorectal cancer Anticancer Res 2011 31 6 2271 2281 21737652
  • Reck M Kaiser R Eschbach C A phase II double-blind study to investigate efficacy and safety of two doses of the triple angiokinase inhibitor BIBF 1120 in patients with relapsed advanced non-small-cell lung cancer Ann Oncol 2011 22 6 1374 1381 21212157